I-MAB (NAS:IMAB)
$ 1.055 -0.04 (-3.64%) Market Cap: 81.84 Mil Enterprise Value: -118.19 Mil PE Ratio: 0 PB Ratio: 0.35 GF Score: 35/100

I-Mab R&D Day Transcript

Jul 20, 2022 / 12:00PM GMT
Release Date Price: $10.08 (+3.17%)
Jingwu Zhang Zang
I-Mab - Founder, Chairman & Acting CEO

First of all, I would like to take this opportunity to welcome you all to our R&D Day. R&D day is an important annual event for the company and has been the company's tradition to showcase our research and pipeline development and share our excitement with investors, experts and our partners.

Without further ado, I would like to take the first 15 to 20 minutes to set a stage for today's R&D presentation and more specifically, discuss how to best position the company in this turbulent market to focus our resources on our key business priorities and deliver high-value milestones and catalysts.

Now what is the company's competitive advantage or differentiation -- over the years, we have successfully demonstrated that I-Mab's competitive advantage and differentiation is our R&D capability in the area of immuno-oncology. We have been focusing on global innovation to develop biologics with first-in-class, best-in-class potential. We have done well in this regard with multiple examples. Since 2016, we have created 3

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot